13.12.2020

11:33

FGFR3 Status in Urothelial Carcinoma

FGFR3 Status Associated With Differential Sensitivity to Platinum-Based Chemotherapy in Urothelial Carcinoma

Urology

מן הרשת

13.12.2020

11:31

Post-surgical ctDNA-positivity in patients with MIUC

Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy

ESMO

מן הרשת

08.12.2020

11:55

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer

updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology

מן הרשת

01.12.2020

17:19

Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors

US Preventive Services Task Force Recommendation Statement

Jama Network

מן הרשת

19.11.2020

16:37

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear

NEJM

מן הרשת

19.11.2020

16:07

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer

An exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab

J Clin Oncol'

מן הרשת

19.11.2020

15:29

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer

an open-label, multicentre, single-arm, phase 2 trial

The Lancet Oncology

מן הרשת

11.11.2020

16:29

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer

an open-label, multicentre, single-arm, phase 2 trial

The Lancet Oncology

מן הרשת

01.11.2020

11:15

FDA grants breakthrough designation to urine-based liquid biopsy for prostate cancer

Urology Times

מן הרשת

01.11.2020

11:14

CTCs Serve as Prognostic Marker for Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

Circulating tumor cell (CTC) count is a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer (mCSPC), according to Amir Goldkorn, MD, who added that the use of CTCs could be of critical importance in future research

OncLive

מן הרשת

01.11.2020

11:12

Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer

A tertiary medical center experience

UroToday

מן הרשת

01.11.2020

11:10

Radiation Therapy, Brachytherapy Outcomes Similar for Localized Prostate Cancer

Long-term survival among men with intermediate-risk prostate cancer did not differ regardless of whether they received stereotactic body radiation therapy (SBRT), dose-escalated external beam radiation (DE-EBRT) or brachytherapy (BT), according to a database analysis

MedScape

מן הרשת

01.11.2020

11:09

Bone Targeted Therapy and Skeletal Related Events in the Era of Enzalutamide and Abiraterone Acetate

for Castration Resistant Prostate Cancer with Bone Metastases - Beyond the Abstract

UroToday

מן הרשת

01.11.2020

11:07

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial

PracticeUpdate

מן הרשת

01.11.2020

11:06

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma

(KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The Lancet Oncology

מן הרשת

FGFR3 Status in Urothelial Carcinoma

FGFR3 Status Associated With Differential Sensitivity to Platinum-Based Chemotherapy in Urothelial Carcinoma

Post-surgical ctDNA-positivity in patients with MIUC

Post-surgical ctDNA-positivity in patients with MIUC associates with higher risk of disease recurrence and identifies patients that may benefit from adjuvant atezolizumab therapy

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer

updated results from a randomised, controlled, open-label, phase 3 trial

Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults With Cardiovascular Risk Factors

US Preventive Services Task Force Recommendation Statement

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer

An exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer

an open-label, multicentre, single-arm, phase 2 trial

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer

an open-label, multicentre, single-arm, phase 2 trial

FDA grants breakthrough designation to urine-based liquid biopsy for prostate cancer

CTCs Serve as Prognostic Marker for Outcomes in Metastatic Hormone-Sensitive Prostate Cancer

Circulating tumor cell (CTC) count is a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer (mCSPC), according to Amir Goldkorn, MD, who added that the use of CTCs could be of critical importance in future research

Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer

A tertiary medical center experience

Radiation Therapy, Brachytherapy Outcomes Similar for Localized Prostate Cancer

Long-term survival among men with intermediate-risk prostate cancer did not differ regardless of whether they received stereotactic body radiation therapy (SBRT), dose-escalated external beam radiation (DE-EBRT) or brachytherapy (BT), according to a database analysis

Bone Targeted Therapy and Skeletal Related Events in the Era of Enzalutamide and Abiraterone Acetate

for Castration Resistant Prostate Cancer with Bone Metastases - Beyond the Abstract

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma

(KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

14.06.2021

מחקרים וחדשות רפואה

תגובות אחרונות

7 הכי נקראות